Relay Therapeutics Inc. (RLAY)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) came out with a quarterly loss of $0.41 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics, Inc. (RLAY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Relay Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 540 | $2,461.42 | $10,168.2 | $7,706.78 | 313.1% |
| BG Bart Gancher Intech Investment Management LLC | 34,101 | $216,503.98 | $674,176.77 | $457,672.79 | 211.39% |
 John H. Burbank III Passport Capital LLC | 2.83M | $48.58M | $56.14M | $7.56M | 15.56% |
| JM John Malone Amundi | 17,726 | $176,373.7 | $353,456.44 | $177,082.74 | 100.4% |
 Joseph Castro Nuveen LLC | 392,691 | $2.66M | $7.83M | $5.17M | 194.26% |
Relay Therapeutics Inc. (RLAY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Relay Therapeutics Inc. ever had a stock split?
Relay Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sanjiv K. Patel CEO | NASDAQ (NMS) Exchange | 75943R102 CUSIP |
| US Country | 202 Employees | - Last Dividend | - Last Split | 16 Jul 2020 IPO Date |
Overview
Relay Therapeutics, Inc. is a cutting-edge clinical-stage precision medicines company deeply invested in changing the landscape of drug discovery. With a keen focus on developing small molecule therapeutics aimed at targeted oncology and genetic disease indications, the company is pioneering efforts to enhance the drug discovery process. Originating under the name Allostery, Inc., the organization rebranded to Relay Therapeutics, Inc. in December 2015, situating its headquarters in Cambridge, Massachusetts. Since its incorporation in 2015, Relay Therapeutics has forged vital collaborations and license agreements with leading entities such as D. E. Shaw Research, LLC, and Genentech, Inc., leveraging advanced computational modeling capabilities and focusing on the analyzation of protein motion to develop novel compounds targeting critical biological pathways.
Products and Services
- RLY-4008: This is an oral small molecule inhibitor targeting the fibroblast growth factor receptor 2 (FGFR2), currently undergoing a first-in-human clinical trial. It is specifically designed for patients with advanced or metastatic FGFR2-altered solid tumors, marking a significant stride forward in targeted oncology.
RLY-4008 represents a pioneering approach to cancer treatment, focusing on harnessing the potential of specifically inhibiting FGFR2 to combat various forms of cancer. The clinical trial aims to evaluate its efficacy and safety in a patient population with few other therapeutic options.
- RLY-2608: This candidate is a leading mutant-PI3Ka inhibitor program, aiming at the phosphoinositide 3-kinase alpha (PI3Ka), a crucial enzyme involved in the signaling pathways that control cell growth and survival.
The development of RLY-2608 centers around its potential to offer a targeted therapy option for patients with tumors driven by mutations in the PI3Ka pathway. Relay Therapeutics’ focus on this molecule underscores the company’s commitment to addressing cancer's genetic complexities.
- Migoprotafib (GDC-1971): As a potent and selective inhibitor of the protein tyrosine phosphatase SHP2, Migoprotafib showcases how small molecule therapeutics can be tailored to interact with critical oncogenic proteins. This oral small molecule acts by binding and stabilizing Src homology region 2 domain-containing phosphatase-2 (SHP2), with its applications being explored as a monotherapy in patients with advanced or metastatic solid tumors.
The collaboration with Genentech, Inc. for the development and commercialization of GDC-1971 (Migoprotafib) highlights its potential to be a breakthrough in cancer therapy, potentially offering new hope to patients with advanced cancers through targeted therapeutic strategies.
